In this episode:
In this podcast first recorded at the 2020 IO360° Summit, Dr Aiman Shalabi, GSK, moderated a cell and gene therapy debate on intrinsic editing vs systemic combination
Participants included:
- Mark O’Hara, MD, University of Pennsylvania
- Saul Priceman, PhD, City of Hope
To learn more about the Immuno-Oncology 360° Conference, please visit IO360Summit.com.
